Kenvue Inc. (KVUE)
Kenvue (KVUE) Q1 Earnings and Revenues Beat Estimates
Kenvue (KVUE) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.24 per share a year ago.
Kimberly-Clark's New Structure Sets Stage for Kenvue Integration
Kimberly-Clark's lean new regional structure is built for speed as it prepares to integrate Kenvue in a $48.7B deal closing in H2 2026.
Kimberly-Clark retains Urdaneta as CFO of combined company after $40-billion Kenvue deal
Kimberly-Clark on Wednesday said its chief financial officer, Nelson Urdaneta, will become the finance chief of the combined company it will create after completing its $40-billion acquisition of Tylenol-maker Kenvue.
Tylenol in pregnancy not linked with autism, Danish study finds
The use of Tylenol by women during pregnancy was not associated with autism in their children, according to results of a nationwide study in Denmark published on Monday.
Kimberly-Clark's Dividend King Status Faces A Big Unknown
Kimberly-Clark Corporation is undergoing major transformation with a JV in Brazil and the $49B Kenvue acquisition. KMB's shift toward premium brands via KVUE increases revenue scale but introduces integration and brand loyalty risks amid consumer trade-down trends. Post-acquisition, leverage will rise to ~2.8x net debt/EBITDA, pausing share buybacks and potentially impacting credit ratings and dividend stability if synergies disappoint.
First Trust Advisors LP Acquires 1,778,475 Shares of Kenvue Inc. $KVUE
First Trust Advisors LP raised its stake in shares of Kenvue Inc. (NYSE: KVUE) by 200.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,667,217 shares of the company's stock after buying an additional 1,778,475 shares
Tylenol use among women dropped after Trump tied it to autism
Tylenol use among pregnant women fell after U.S. President Donald Trump linked autism to the over-the-counter pain relief medicine, according to an analysis of U.S. emergency room prescribing patterns published in the UK medical journal Lancet.
KVUE vs. PG: Which Stock Is the Better Value Option?
Investors looking for stocks in the Consumer Products - Staples sector might want to consider either Kenvue (KVUE) or Procter & Gamble (PG). But which of these two stocks offers value investors a better bang for their buck right now?
Kenvue Tops Q4 Earnings Estimates, Advances Toward Kimberly-Clark Deal
KVUE reports solid Q4 results, with margin gains and broad-based global growth, while moving closer to its planned Kimberly-Clark acquisition.
Kenvue tops Q4 forecasts as Kimberly-Clark deal advances
Kenvue Inc (NYSE:KVUE) reported fourth quarter results that topped Wall Street expectations, while the consumer health company also outlined restructuring steps ahead of its planned combination with Kimberly-Clark. For Q4, Kenvue posted adjusted earnings per share of $0.27, beating analyst estimates of $0.22.
Kenvue Surges as Earnings Beat, Kimberly-Clark Merger Gains Steam
Kenvue (NYSE: KVUE) reported fourth-quarter results yesterday that exceeded analyst expectations, with adjusted EPS of $0.27 beating the FactSet estimate of $0.22 by 23%.
Kenvue (KVUE) Beats Q4 Earnings and Revenue Estimates
Kenvue (KVUE) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.26 per share a year ago.
